Professorial Faculty
Technical University of Munich

Prof. Dr. Stefan Hanns Engelhardt

Professorship

Pharmacology and Toxicology

School

TUM School of Medicine and Health

Contact Details

Business card at TUMonline

Academic Career and Research Areas

Professor Engelhardt conducts research in the field of signal transduction in the cardiovascular system.

Professor Engelhardt (*1969) studied medicine at the universities of Regensburg, Munich and Harvard. After his master's degree at the Max Planck Institute of Biochemistry and his PhD and postdoc at the University of Würzburg, Professor Engelhardt headed a junior research group at the DFG Center for Experimental Biomedicine (Rudolf Virchow Center). He was a professor of pharmacology at the University of Würzburg, before being appointed to the Chair of Pharmacology and Toxicology at the TUM in 2008. He also serves as speaker of the German Center for Cardiovascular Research (DZHK) in Munich.

Awards

  • Outstanding Achievement Award, European Society of Cardiology (2009)
  • Arthur-Weber Prize, German Cardiac Society (2006)
  • Oskar Lapp Prize, German Cardiac Society (2005)
  • Biology Prize, Academy of Science at the Universitiy of Göttingen (2004)
  • Hengstberger Prize, German Cardiac Society (2004)

Key Publications

K. A. Ziegler, A. Ahles, A. Dueck, D. Esfandyari, P. Pichler, K. Weber, S. Kotschi, A. Bartelt, I. Sinicina, M. Graw, H. Leonhardt, L. T. Weckbach, S. Massberg, M. Schifferer, M. Simons, L. Hoeher, J. Luo, A. Erturk, G. G. Schiattarella, Y. Sassi, T. Misgeld, and S. Engelhardt. 2023. Immune-mediated denervation of the pineal gland underlies sleep disturbance in cardiac disease. Science 381: 285-290.

Abstract

C. Beck, D. Ramanujam, P. Vaccarello, F. Widenmeyer, M. Feuerherd, C. C. Cheng, A. Bomhard, T. Abikeeva, J. Schadler, J. P. Sperhake, M. Graw, S. Safi, H. Hoffmann, C. A. Staab-Weijnitz, R. Rad, U. Protzer, T. Frischmuth, and S. Engelhardt. 2023. Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage. Nat Commun 14: 4564.

Abstract

D. Esfandyari, B. M. G. Idrissou, K. Hennis, P. Avramopoulos, A. Dueck, I. El-Battrawy, L. Gruter, M. A. Meier, A. C. Nager, D. Ramanujam, T. Dorn, T. Meitinger, C. Hagl, H. Milting, M. Borggrefe, S. Fenske, M. Biel, A. Dendorfer, Y. Sassi, A. Moretti, and S. Engelhardt. 2022. MicroRNA-365 regulates human cardiac action potential duration. Nat Commun 13: 220.

Abstract

Y. Sassi, P. Avramopoulos, D. Ramanujam, L. Gruter, S. Werfel, S. Giosele, A. D. Brunner, D. Esfandyari, A. S. Papadopoulou, B. De Strooper, N. Hubner, R. Kumarswamy, T. Thum, X. Yin, M. Mayr, B. Laggerbauer, and S. Engelhardt. 2017. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun 8: 1614.

Abstract

T. Thum, C. Gross, J. Fiedler, T. Fischer, S. Kissler, M. Bussen, P. Galuppo, S. Just, W. Rottbauer, S. Frantz, M. Castoldi, J. Soutschek, V. Koteliansky, A. Rosenwald, M. A. Basson, J. D. Licht, J. T. Pena, S. H. Rouhanifard, M. U. Muckenthaler, T. Tuschl, G. R. Martin, J. Bauersachs°, and S. Engelhardt°. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984.
° co-corresponding authors

Abstract

If you wish your profile to be changed or updated please contact Franz Langer.